LONDON, Oct 2 (Reuters) – Europe’s medicines regulator has
endorsed a scheme to publish detailed clinical reports
underpinning new drug approvals from next year, though
campaigners for full transparency said they were concerned some
data would still be missing.
The London-based European Medicines Agency (EMA) has been at
the centre of a row about divulging trials data for the past two
years, following concerns over undisclosed data for certain
drugs such as Roche’s flu pill Tamiflu.
MADRID (Reuters) – A raft of new cancer drugs promise better, longer-lasting treatments with fewer adverse side effects — but their high cost is a growing concern.
Drugs that help the body’s own immune cells fight tumors are expected to be used in multi-drug cocktails, pushing the price of therapies costing more than $100,000 a year even higher.
MADRID, Sept 29 (Reuters) – Rival two-pill combinations for
melanoma from Roche and GlaxoSmithKline had
similarly good results in separate clinical trials, leaving
doctors with little to choose between the two skin cancer
The latest findings will fuel a wider debate about the
optimal treatment of melanoma as a new generation of
immune-stimulating injections offers an alternative way to fight
the deadliest form of skin cancer.